Business Context and Reporting Period
This Form 8-K is a current report filed by resTORbio, Inc. (not Adicet Bio, Inc.) on November 5, 2018. The filing discloses changes to the Company's Board of Directors, including the appointment of a new director and the resignation of an existing director.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to director compensation:
- Annual Cash Retainer: $30,000 for the new director, paid quarterly in arrears.
- Stock Option Grant: 28,828 shares at an exercise price of $11.82 per share.
Material Changes
The primary material change is the composition of the Board of Directors:
- Appointment: Michael J. Grissinger was appointed as a Class II director, effective November 5, 2018. He will serve until the 2020 annual meeting or until a successor is elected.
- Resignation: Daphne Zohar resigned from the Board and all committees, effective immediately upon Mr. Grissinger's appointment. The resignation was not due to any disagreement with the Company.
Outlook, Risks, and Contingencies
Management Commentary: The Company believes Mr. Grissinger is qualified based on his substantial experience leading pharmaceutical companies.
Contingencies: The Company entered into an indemnification agreement with Mr. Grissinger. Under this agreement, the Company may be required to indemnify him for expenses, including attorneys' fees, judgments, fines, and settlement amounts incurred in actions arising from his service as a director.
Risks: No specific operational or financial risks were disclosed in this filing.
Investor Verification Checklist
- Verify the exact vesting schedule of the 28,828 stock options granted to Michael J. Grissinger (33% on first anniversary, remainder ratably over two years).
- Confirm the total number of directors on the Board following the resignation of Daphne Zohar and appointment of Michael J. Grissinger.
- Review the attached press release (Exhibit 99.1) for additional context on the strategic rationale for the board changes.